Latest Hybridoma Technology Stories
UI finding might help improve 'liquid biopsy' approach for detecting cancer cells in blood A surprising discovery about the physical properties of cancer cells could help improve a new diagnostic approach—a liquid biopsy—that detects, measures, and evaluates cancer cells in blood. Cancer cells circulating in the bloodstream can form metastases—new tumors. Detecting these rare circulating cancer cells in a blood sample is much less invasive than a standard tumor biopsy, and could...
WHEATON Industries has acquired the CELLine Bioreactor Flask Line for Antibody and Protein Production from Wilson Wolf Manufacturing Corporation Millville, NJ (PRWEB) July 09, 2012 WHEATON has acquired the CELLine dual membrane, cell culture flasks from Wilson Wolf Manufacturing Corporation. WHEATON has also entered into a long term strategic partnership with Wilson Wolf Manufacturing Corporation for further product development in high density cell culture devices for the production of...
MENLO PARK, Calif., June 8, 2011 /PRNewswire/ -- ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Dip and Read(TM) Anti-Mouse IgG Fc Capture (AMC) biosensor for use on the company's Octet® instrumentation platform. The new biosensor enables high-throughput rapid kinetic characterization and screening of mouse antibodies and other Fc-containing proteins with...
BERGISCH GLADBACH, Germany, May 12, 2011 /PRNewswire/ -- Miltenyi Biotec, the only company to offer a seamless experimental integration path from sample preparation through cell separation, culture, and analysis for primary cells, today entered into a strategic alliance with TeutoCell, a provider of cutting edge cell culture technology. The new partnership will broaden that experimental integration path to include cell culture for biomanufacturing with the addition of five novel cell...
ROCKVILLE, Md., Jan. 20, 2011 /PRNewswire/ -- OriGene Technologies, Inc. has recently achieved a significant milestone in its quest for developing an assay for every human protein through the release of 1,500 mouse monoclonal antibodies under the TrueMAB brand. Each TrueMAB antibody is specifically developed with full-length human proteins produced in HEK293T cells and validated for critical research and diagnostic needs requiring improved antibody sensitivity and specificity. Greater than...
COLUMBIA, Md., Aug. 23 /PRNewswire-USNewswire/ -- Precision Antibody(TM) announced today its selection by the United States Environmental Protection Agency (EPA) to develop monoclonal antibodies to two species of Cryptosporidium ("Crypto"), an intestinal parasite that has emerged over the past 20 years as one of the most common causes of waterborne illness in the United States. According to the U.S. Centers for Disease Control and Prevention, between 2006-2008, Crypto was responsible for 42...
BURLINGAME, Calif., Aug. 9 /PRNewswire/ -- Epitomics, Inc., the rabbit monoclonal antibody company, announces today the launch of EP Clone(TM) Rabbit Monoclonal Antibodies and their detection systems for pathology applications. These diagnostic immunohistochemistry (IHC) products are manufactured by the In Vitro Diagnostic (IVD) Division of the Company. This new line of products are developed in compliance with regulation for IHC antibodies and detection systems in the United States,...
HASSELT, Belgium, July 27 /PRNewswire-FirstCall/ -- Biotechnology company MabCure, Inc. (OTC Bulletin Board: MBCI) today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure's serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints...
EUREKA project E! 3424 RECAN has developed a range of unique and highly specific monoclonal and polyclonal antibodies "“ the proteins produced in the blood which counteract bacteria, viruses or cancerous cells. This was achieved by first producing a number of recombinant proteins which are important components of cellular signaling pathways. These proteins themselves have direct uses in immunization and experimental studies. A further key advance is the incorporation of novel fluorochrome...
THOUSAND OAKS, Calif., Feb. 8 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa® (zoledronic acid) in the treatment of bone metastases in 1,901 men with advanced prostate cancer met its primary and secondary endpoints. Denosumab demonstrated superiority over Zometa for both delaying the time to the first on-study skeletal related event (SRE) (fracture, radiation to bone, surgery to bone or spinal...
